Rheumatoid arthritis (RA)
Costantino Pitzalis, MD, PhD, FRCP
QMUL
Bromley Kent, United Kingdom
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Roche: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
This session will summarize recent work that uses gene-expression profiles, blood interferon-response-gene expression, and patterns of clinical and genetic variation to predict responsiveness to medications in patients with rheumatoid arthritis.
Speaker: Costantino Pitzalis, MD, PhD, FRCP – QMUL